GO
| HSI1 | 25,042.71 | +291.93 | 202.73B |
| HSCEI1 | 8,339.63 | +114.23 | 56.78B |
| Back Zoom + Zoom - Block Traded | |
|
2026-09-21 12:03:21 Morgan Stanley issued a research report stating that the "15th Five-Year Plan" for Pharmaceutical Industry Development mentioned a target for China's innovative drug industry to achieve a CAGR of more than 20% by 2030, equivalent to expanding the industry's scale to around 2.5x the current level. The plan also explicitly supports Chinese biopharmaceutical companies in co-developing and commercializing products with global partners, while strengthening intellectual property protection and coordination of regulatory standards, helping to ease geopolitical concerns. Morgan Stanley also mentioned that the plan prioritizes the development of AI-enabled applications such as target discovery and molecular design/optimization. In the medical devices and diagnostics segment, the plan supports high-end medical devices and precision diagnostics/treatment, targeting the launch of 200 or more innovative medical devices by 2030. The broker maintained an Attractive sector view on China's healthcare industry. ~ AASTOCKS Financial News Website: www.aastocks.com | |